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Background Porphyria cutanea tarda (PCT) is characterized by fragile skin with blis-
tering on sun-exposed areas. Symptoms typically develop in late adulthood and
can be triggered by iron overload, alcohol intake, oestrogens and various liver
diseases. Treatment consists of phlebotomy to reduce iron, or increasing urinary
porphyrin excretion by administering chlorochin. To optimize patient care,
health personnel need to understand the subjective experiences of PCT.
Objectives To explore the experiences of persons with PCT with regard to symp-
toms, treatment, follow-up and prevention of the disease.
Methods Interpretive description was used as a qualitative approach. Twenty-one
participants attended three focus groups. All participants had experienced PCT
symptoms during the last 5 years.
Results Participants’ experiences varied from trivializing symptoms and fragile skin
to what was described as a desperate situation, with huge blisters, skin falling off
and feeling as if one was in a ‘horror movie’. For some, itching was very trou-
blesome, preventing sleep and delaying skin healing. In managing PCT a shift in
focus from skin to blood was described. PCT was perceived as a chronic and sys-
temic disease causing a range of health problems. Strategies for preventing symp-
toms ranged from doing nothing to frequent controls and check-ups.
Conclusions Participants had a systemic perception of PCT, and a tendency to attri-
bute a range of health problems to the condition. This study adds insight into
the experiences patients have with PCT.
What’s already known about this topic?
• Photodermatoses can have a profound impact on quality of life, but little is known
of the subjective experiences of porphyria cutanea tarda (PCT).
What does this study add?
• Participants’ symptoms varied from fragile skin to what was described as a desper-
ate situation.
• Participants had a systemic perception of PCT and a tendency to attribute a range
of health problems to the condition.
• Itching was reported to be a severe problem for some participants.
Porphyria cutanea tarda (PCT) is a rare disease characterized
by fragile skin and blistering on sun-exposed areas. Increased
urinary porphyrin excretion causes red- or dark-coloured urine.
Symptoms typically develop in late adulthood and can be
triggered by hepatic iron overload, alcohol intake, oestro-
gens, hepatitis C and various liver stressors, in combination
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with exposure to light. The prevalence of symptomatic dis-
ease is estimated to be 1 in 10 000.1,2 The condition exists
in both a familial and sporadic subtype. Compared with
25% of cases worldwide, about 50% of cases of PCT in
Norway are hereditary because of two founder mutations.3,4
Penetrance is very low, and only an estimated 10% of
mutation carriers develop symptoms throughout life. Treat-
ment consists of avoidance of precipitating factors, phlebot-
omy to reduce iron or increasing urinary porphyrin
excretion by administering chloroquine.4
It might take 6–15 months before complete clinical and
biochemical remission is reached,5,6 but the prognosis is
good, and many patients experience lifelong remission. To
detect relapse, urinary porphyrin concentration, iron and liver
functions should be assessed annually.4,7
The principal aim of the Norwegian Porphyria Centre is to
optimize the diagnosis, treatment and follow-up of patients
with porphyria. Although the clinical benefits of mutation
screening are controversial,4 distinguishing between sporadic
and familial cases appears to be important to many patients
and their relatives,3 and NAPOS therefore offers, in hereditary
cases, predictive genetic testing and counselling to at-risk adult
family members.
Photodermatoses can have a high psychological impact.8
Jong et al.9 investigated quality of life (QoL) in patients
with a range of photodermatoses, including PCT. They con-
cluded that, overall, photodermatoses had a major impact
on QoL, but that PCT had a lower impact on QoL than did
other cutaneous porphyrias. Very little knowledge of the
psychosocial impact of PCT is available and more informa-
tion on the subjective experiences is therefore needed to
secure optimal treatment, follow-up and counselling of this
group. The aim of the present study was therefore to
explore the experiences persons with PCT have regarding
symptoms, treatment, follow-up and prevention of the dis-
ease.
Methods
This study was based on interpretive description, which is a
well-documented qualitative approach with emphasis on clini-
cal practice and exploration of health-related issues.10–12 Focus
groups with interactive discussions were deemed appropri-
ate.13 The study complied with the principles of the Declara-
tion of Helsinki and was approved by the Norwegian regional
ethics committee (2012/1078).
Recruitment
A convenience sample was recruited in connection with a
biennial patient seminar arranged by NAPOS in 2012.12
Information regarding the focus groups was included with
invitations to the seminar. Experience with symptoms dur-
ing the last 5 years was set as the inclusion criterion.
Forty-six people with PCT participated at the seminar and
23 provided written consent to participate in the focus
groups. Two were excluded because of clinical remission
exceeding 5 years.
Data production and participants
The patient seminar consisted of joint sessions and lectures
on symptoms and treatment, in addition to conversation
groups for patients to share their experiences. Three focus
groups with seven participants were held over two consecu-
tive days at the seminar.14 In light of the rich information
provided, the sample size was deemed satisfactory.12 The
interviews lasted approximately 90 min. The participants
included 11 women and 10 men, aged 31–77 years. Three
participants reported having haemochromatosis (Table 1).
The interviews were moderated by the first author (J.A.),
who is experienced in counselling patients with porphyria.
One co-moderator participated in the first two groups while
a second participated in the third group. The interviews were
semistructured and focused on three main themes with sub-
questions. The main themes of the interview guide were: (i)
experience with symptoms; (ii) treatment; and (iii) future
expectations. Emerging themes that were not addressed by
the interview guide were followed up in consecutive
interviews.
Analysis
Analysis was performed in accordance with interpretive
descriptive guidelines and was also influenced by systematic
text condensation.11,12,15 Analysis was primarily performed
by the first author (J.A.), with discussions and guidance
from the other authors (E.G., S.S. and M.R.). Audio record-
ings of the interviews were transcribed verbatim and ini-
tially read as a whole. In the first step, focus was on
reflections and main impressions and four preliminary
themes were identified: (i) large variations in symptom
experience; (ii) taking control; (iii) treatment; and (iv) pre-
vention of symptoms. In step two, coding and text conden-
sation were performed based on these themes, while special
attention was given to avoidance of premature closure of
coding.12 Coding was first conducted cross-case, followed
by longitudinal coding at an individual level.15 In step
three, coding was elaborated with subgroups and further
text condensation. Step four was an iterative process where
focus shifted from the decontextualized codes and the tran-
scripts as a whole; based on this, a synthesis of the coded
material was presented as three main themes with sub-
themes. For validation, the full transcripts were re-read
several times and systematically searched for data that chal-
lenged the results.
Results
The results are presented as three main themes with subsec-
tions. Quotes are used to elucidate and elaborate the experi-
ences of the participants. Participants are anonymized.
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Theme 1: large variations in participants’ experiences of
skin symptoms – from trivializing to nightmare
descriptions
Trivializing symptoms
Participants’ skin symptoms typically presented as small blis-
ters or very fragile skin, and simple things like putting hands
into a pocket could cause skin trauma. Slow-healing sores
were suspected by participants to have been caused by burn-
ing or cutting themselves without noticing, or from allergic
reactions to chemicals or similar incidents. Discoloured urine
was explained by drinking too little. This tendency to trivialize
PCT symptoms as being caused by ‘normal things’ resulted in
participants waiting to seek medical expertise, which contrib-
uted to a delayed diagnosis. Several persons explained that
other people’s comments about their skin made them realize
they needed to see a doctor. When they finally did, diagnosis
was often missed, especially if they were not referred to a der-
matologist. Veronica explained:
I haven’t had those really large, fluid-filled blisters. But
I had very small blisters and really fragile skin. I’ve had
to be very careful not to bump into things when it was
at its worst, because it didn’t take much, just barely
scraping with a fingernail. And it never healed; it just
itched. And also the part with the coloured urine,
because that started long before the symptoms on my
hands did.
Itching – an underestimated problem?
It became evident that itching was a problem, with some con-
sidering itching to be the worst aspect of PCT. Itching was
attributed to skin healing and seen as a sign of rising porphy-
rin levels. Participants would itch both when experiencing
symptoms and when in remission. The itching was predomi-
nant at night, and would typically start after going to bed. It
was debatable whether this was because of the warmth of the
bed, or because it was more noticeable at this time. The itch-
ing disrupted or prevented sleep, and already fragile skin was
easily ruptured, resulting in bleeding, further delaying skin
healing and increasing the probability of infection. Some slept
with gloves on to prevent inadvertently hurting themselves.
Nick said:
It itches so much [several nods in agreement], so that’s
what I feel is the biggest problem. And then you lie
awake at night and you scratch and it bleeds. Because
of this, it never heals because it is scratched too often.
. . . It is there all the time, but it is at night that I
scratch because I cannot help myself. So yes, that is
when I notice it the most. It itches all the time, but that
is when you might hurt yourself.
Table 1 Participant characteristics
Sex Age (years)
Year of elevated urinary
porphyrin levels Type of PCT HFE status
Group 1
Nick 61 2001, 2009 Sporadic Normal
Frank 59 2009 Sporadic Heterozygous H63D
John 56 2005, 2008 Familial Normal
Linda 60 2008 Sporadic Normal
Michelle 62 1998, 2009 Sporadic Normal
Nora 34 2012 Sporadic Homozygous C282Y
Alice 52 2010 Familial Normal
Group 2
Peter 67 2006 Familial Normal
Jack 56 2004, 2008 Familial Normala
Simon 57 2010 Familial Normal
David 68 2005 Sporadic Normal
Andrea 62 2006 Sporadic Heterozygous C282Ya
Lucy 66 2010 Sporadic Normal
Julie 58 2008 Sporadic Heterozygous H63D
Group 3
Tony 77 2001, 2009 Unknown Unknown
Martin 51 2009 Familial Heterozygous C282Ya
Sandra 64 2011 Familial Normal
Lilly 58 2009 Familial Normal
Monika 55 2009 Familial Heterozygous C282Y
Rachel 56 2010 Familial Heterozygous C282Y
Veronica 31 2009 Familial Normal
PCT, porphyria cutanea tarda; HFE, haemochromatosis gene. aParticipants reported having haemochromatosis.
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Skin symptoms at their worst: ‘living in a horror movie’
At its worst, PCT was painful, causing large fluid-filled blisters
that would rupture, run and cause fragile skin to fall off.
Fluids from blisters would squirt when shaking hands with
others, and one explained that she drained her blisters with
hypodermic needles. Bandaging was time-consuming and,
when removed, skin would be ripped off. Participants would
wear hats and cotton gloves to protect their skin and hide
their symptoms from others, which would result in comments
that they were ‘snobs’. One participant had to empty blister
fluids from his gloves while working. Everyday situations such
as putting on shoes could cause the skin to peel off and some-
times these areas would become infected. When the PCT
symptoms were at their worst, the situation was experienced
as dramatic and described as ‘being in a horror movie’. Lilly
said:
I was just desperate! And my grandchildren? At that
point, I didn’t know if I could touch them or give
them a hug or what, you know? It just kept running! It
was burning! . . .. So, it was a desperate situation, also
because you don’t know what it is. I was thinking, “Oh
my god! Am I going to lose the skin on my entire
body?” You know? Can no one help me?
Theme 2: a skin disease, a blood disease or something
in between?
A shift in focus from skin to blood
After their diagnosis was established, participants described
a shift in focus. One participant explained that she was sur-
prised when she understood that PCT was not a simple skin
disease. At first, PCT presented as skin symptoms, and diag-
nosis was based on patients seeking medical care for this.
However, after diagnosis was established, the focus shifted
from the skin to the blood. The use of phlebotomy as a
treatment for PCT emphasized this. Blood samples, blood
values and phlebotomy introduced a technical aspect, and
many participants displayed a keen interest. They brought
copies of their blood work to the focus groups and com-
pared and discussed who had the highest ferritin levels and
at what level they preferred to undergo prophylactic phle-
botomy. Nora said:
Yes, and it’s like I can feel something crawling in my
skin. And after I learned about this, I just feel the por-
phyrins flying around.
Suspecting porphyria cutanea tarda caused more health
problems than skin symptoms
Many participants suspected PCT caused health problems that
were not limited to the skin. They felt that porphyrins were
in their blood, and that genes and enzymes were involved,
which made them comment that things in the body were
connected. A variety of symptoms caused by PCT were pro-
posed and the participants showed a growing need to find
legitimate reasons for other health complaints. Maria
explained:
Perhaps it is a bit more complicated than what is
believed? That there are actually more symptoms? That
more things are connected to it? Because this is some-
thing that happens inside the body; that’s what I think,
that there might be.
Their suspicion was explained by the fact that the symptom
in question arose at the same time as their skin symptoms
appeared, and that other explanations had not been detected.
Participants learned that they had similar health problems after
speaking with other patients, which confirmed their suspi-
cions. Fatigue was explicitly discussed as being related to PCT,
but known acute porphyria symptoms, such as stomach pains
and muscle aches, were also attributed to PCT, both by partic-
ipants and sometimes by local health personnel. Participants
questioned why these symptoms were not recognized by med-
ical experts as being related to PCT and pointed to the need
for further research. However, the focus on what could be
attributed to PCT was so evident in the groups that some par-
ticipants commented that surely not everything could be
caused by the disease.
Theme 3: managing porphyria cutanea tarda – strategies
for prevention, treatment and controls
Preventive strategies: frequent controls, taking calculated
risks or doing nothing?
PCT was perceived as a chronic condition that patients needed
to manage for the remainder of their lives. For some, this
meant frequent controls and a vigilant lifestyle, with a focus
on eating habits, avoiding the sun and generally being careful.
For others, prevention involved taking blood samples and hav-
ing control intervals. Control intervals varied greatly, from
having ferritin levels never checked to having them checked
every 2 weeks, every month and twice a year. The merits of
this were debated by participants, and the more ‘experienced’
patients with PCT were asked for advice as to how often they
should be tested, which test should be done and who should
perform them. A few participants said they did nothing to
prevent PCT. As Lilly said, ‘I have a disease, but I’m not ill’.
Most took calculated risks and would enjoy alcohol, sun and
good food, but in moderation. They said they knew they
risked skin symptoms, but it was worth it. However, the sus-
picion that PCT caused other problems was more worrying.
Lilly said:
I think about it. But I choose to do it. And I think, like,
if I’m traveling to sunny places, if I happen to get a
blister, well that’s just. . . I have a blister, blood samples
and bloodletting. But what I might think about
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sometimes is, what does it do to other things in the
body? Right? I’m thinking cirrhosis. Kidney failure? I
mean, what if I defy this and perhaps avoid getting a
blister. But perhaps I got it because I didn’t take the
precautions I should. And I just used bloodletting as a
way to exceed my limitations. Do you understand what
I’m saying? Because I don’t want that, but this is some-
thing you don’t know a lot about yet. Right? What it
does to other organs? Because if it’s just a rash that can
be treated with draining blood? Well, then we can just
do whatever we want, can’t we?
Phlebotomy: simple and effective, but also demanding
and exhausting
Phlebotomy was viewed as very effective and provided rapid
relief from skin symptoms. Participants described the process
of letting blood as uncomplicated and easy, but, when they
were asked for further details, aspects that were more prob-
lematic emerged. There were discussions as to whether partici-
pants could lose important components of the blood that their
bodies needed. Some explained they would not drive a car or
ride a bicycle the same day, or they needed to take the day
off because they would get very tired. Several had stories of
fainting and of ‘going too low in blood values’, some to the
point that hospitalization was considered. Andrea dreaded hav-
ing phlebotomies:
Ah, I just felt that I was sweating and I was just about
to faint. So now when I am to let blood, it never used
to bother me, but now! Uh! Will they hit the spot or
not? So I start sweating already then. Because when the
needle is inside, and they start looking for the vein.
No. I’m finished. I dread it! Really!
Disagreement over the genetic testing of family members
Participants agreed that genetic testing was a choice that every
individual needed to make for themselves and that whatever
choice was made should be respected. There was disagreement
as to whether they would recommend testing of healthy fam-
ily members. For some, knowledge of genetic status was very
useful; for others, it was a cause of unnecessary worry. Several
pointed out that knowledge of PCT could be acquired without
genetic testing. Moreover, participants who did not worry
much about their own PCT were anxious about whether their
children and grandchildren had inherited the predisposing
gene. Exactly how genes were involved and how this would
affect their health seemed to be unclear and contributed to
making PCT more serious, as the following quote from Julia
illustrates:
I’ve told both my sisters, they know I have this. But
they weren’t interested in testing themselves and one of
my sisters, she has two grandchildren, she didn’t even
want them to know that I have this. This was in regards
to not wanting it to ruin their chances of having chil-
dren. It was their choice.
Discussion
This was a qualitative study and the transferability of results
must be viewed in relation to context and the sociocultural
setting.16 PCT is associated with haemochromatosis,17 hepatitis
and certain lifestyle factors, such as the intake of alcohol,
which should be considered when interpreting the results. In
the present study, all participants claimed to have normal or
restricted alcohol consumption, and hepatitis and alcohol as
predisposing factors therefore probably do not influence the
results or their interpretations. However, the psychosocial
stigma connected to hepatitis and alcohol abuse might have
prevented persons from volunteering to participate in the
focus group or limited their willingness to share this with the
group, a common problem in research based on voluntary
participation. The interviews were held in association with a
patient seminar, which might have heightened the partici-
pants’ awareness of PCT and thus affected their reflections.
This might have contributed to richer information, which is
desirable in qualitative studies. We argue that participants’
awareness does not compromise the validity of the study, but
rather reflects that human experiences cannot be reduced or
separated from their context.
The results showed a large variation in experiences, from
trivializing symptoms to very dramatic symptoms with a great
psychosocial impact on those afflicted. This is interesting in
view of the findings of Jong et al.,9 where PCT had a lower
impact on QoL, measured by the Dermatology Life Question-
naire Index, (DLQI), than other cutaneous porphyrias. That
the DLQI did not capture this variation in experiences is, per-
haps, not surprising. Health-related quality of life measures
are important for the assessment of disease severity, especially
in nonlife-threatening diseases such as skin diseases.18 How-
ever, they are especially aimed at generalization through a
focus on central tendencies, and condition-specific instruments
such as the DLQI are designed to be responsive to change.19
Both these aspects can be problematic considering that there
were only 12 people with PCT included in the study of Jong
et al.,9 and they were likely in clinical remission.9 However,
the qualitative design of the present study was aimed directly
at exploring health issues and providing substantive and rich
descriptions of the participants’ experiences with PCT. We
argue that focus groups based on interactive discussions might
be especially suited for capturing and elaborating the diversity
of experiences of participants in clinical remission.
Some participants with PCT mentioned itching to be a trou-
blesome symptom. Although pruritus is not well documented
in PCT, it has been reported previously.20 Itching is common
in many skin conditions and is likely to delay skin healing,
and is associated with reduced QoL, depression and sleep dis-
turbances.21–24 Consequently, this unsuspected finding war-
rants further investigation. To obtain more information on
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this topic, the Norwegian Porphyria Registry has introduced
this as a variable in the questionnaire sent to patients.
Based on the experiences of the participants in this study,
venesection was an acceptable first choice in treatment; how-
ever, some problematic aspects were introduced and, as low-
dose chloroquine is widely used,4 this might be preferable for
some patients. Our findings suggest that too vigilant a strategy
in the prevention of symptoms might lead to medicalization
rather than benefitting the patient. To the best of our knowl-
edge, there seems to be a lack of data regarding biochemical
and clinical relapse frequency. However, an annual assessment
of urinary porphyrin concentration and iron metabolism is
suggested in the detection of relapses.4 Although PCT has been
associated with changes in glucose metabolism,25 and an
increased risk of liver cancer,26 the mechanisms are unclear
and do not warrant the frequent check-ups (every 2 weeks or
every month) reported by some participants.27–29
PCT is generally defined as a skin disease but, aetiologically,
it is also a hepatic and metabolic disorder.5,30 Because the
symptoms are of a cutaneous nature, one would expect that
the patients experienced PCT as a skin condition. However,
participants in this study described a shift in focus from skin
to blood and began to perceive PCT as a chronic and systemic
disease. The tendency to attribute health problems to PCT was
striking. We are all ‘na€ıve psychologists’ seeking to explain
why events occur and to attribute causal explanations.31
According to the common sense model (CSM) of illness,32,33
there are five components of illness representations that help
people make sense of their symptoms: the identity or the label
given to the condition; the perceived cause of the condition;
the predictive understanding of how long the condition will
last; the individual’s beliefs about the consequences of the
condition; and whether the condition can be cured or con-
trolled.34 In this case, the identity of the condition is ‘por-
phyria’. Porphyrias are a group of diseases, and separating
PCT from other porphyrias can be difficult for both patients
and healthcare providers. Patients with PCT may perceive the
disease as being chronic and systemic because porphyrins,
enzymes, blood and genes are involved, and treatment consists
of bloodletting. This perception can, in turn, explain why par-
ticipants in this study attributed a number of their health
problems to PCT. The CSM uses the perception of the condi-
tion to guide which further actions are taken.34 Lilly stated
that medical experts do not fully understand the possible
long-term complications that this patient group might expect,
and therefore phlebotomies cannot be an ‘easy fix’ if symp-
toms arise. As Lilly commented, ‘if it’s just a rash that can be
treated with draining blood, well, then we can just do what-
ever we want to, can’t we?’ The genetic component of PCT
also seemed intriguing to the participants. A worry that a PCT
mutation might prevent anyone from having children, as was
the case in the family of one participant, emphasizes that the
perceived cause of the condition and the understanding of its
consequences should not be underestimated. When addressing
the issue of symptoms, consequences and controllability of
PCT in clinical consultation, it is therefore important to
recognize that the patient’s illness representation can influence
perception of risk and how they express and act upon this
information.
The results show that, at their worst, PCT symptoms can be
experienced as dramatic, and that a shift in focus from skin to
blood after establishing the diagnosis led to the perception of
PCT as a chronic, systemic disease that may cause a range
of unknown health problems. This suggests there is a need for
information and reassurance in clinical consultations, and as
long as patients are in biochemical remission and follow con-
trol guidelines,4 there is little reason for them to expect health
problems related to PCT. The effects of itching in PCT should
not be underestimated and was reported to be a severe prob-
lem for some participants. It is important that physicians and
healthcare personnel, as well as specialist centres that give
advice on PCT, are aware of the differences in how the
patients experience their disease, and that many of them expe-
rience it as much more than a skin disease, so that patient care
and disease management can be optimized.
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